Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Posted: 1 May 2024 Pathios Therapeutics Limited (“Pathios”), a biotech company focused on the development of first-in-class therapies for cancer, today announced that the company has raised $25 million in the first close of a Series B financing.…
ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator
Posted: 1 May 2024 ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that the U.S. Food and Drug Administration (‘FDA’) has…
Australian community organisations addressing viral hepatitis receive AU$400,000 via global Gilead ALL4LIVER Grant program
Posted: 1 May 2024 Today, on World Liver Day, Gilead Sciences Australia has announced nine local community organisations addressing viral hepatitis will receive a combined AU$400,000 via the global Gilead ALL4LIVER Grant. The recipients were selected by an…
Logistics360 opens second branch in Australia
Posted: 26 April 2024 Following the success of our operation in Melbourne, we are pleased to open a second branch in Brisbane to better serve the local area. The new office is located close to Brisbane airport which…
Championing women innovators in healthtech
Posted: 29 April 2024 Three extraordinary women, who are driving change in the healthtech industry, are recipients of 2024 BioMelbourne Network Women in Leadership Awards. These innovators are entrepreneurs who are inspiring the next generation of scientists and…
AusBiotech announces incoming CEO
Posted: 23 April 2024 Australia’s industry body for biotechnology, AusBiotech, has announced ex-Sanofi leader Rebekah Cassidy as its incoming Chief Executive Officer. Rebekah is an experienced leader with extensive strategy, policy, and media proficiency, coupled with deep health…
From Mines to Medicines – Australia Poised to Lead a Life-saving Revolution in Radiopharmaceuticals
Posted: 19 April 2024 A new discussion paper from MTPConnect reveals how Australia is ready to play a leading role in the rise of the global radiopharmaceutical industry, as advanced therapies drive significant investment and rapid expansion. Radiopharmaceuticals…
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76
Posted: 19 April 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreement with the Centre for Human…
New arrivals boost Hudson’s inflammation research leadership
Posted: 19 April 2024 Hudson Institute’s reputation as a leader in inflammation research has been boosted by the appointment of two specialists in the field. Director and CEO Professor Elizabeth Hartland today announced that Professor Carl Walkley and Dr Sophia…
Increased monitoring capacity of deadly prion diseases
Posted: 19 April 2024 A state-of-the-art service based at The Florey is increasing its capacity to protect the public from the fatal brain condition Creutzfeldt-Jakob disease (CJD). The rare neurodegenerative illness, caused by misfolded proteins called prions in…
Melbourne home to one-of-a-kind electron microscope
Posted: 19 April 2024 A suite of three electron microscopes, including one of the highest resolution microscopes in the world, now calls Monash home, helping scientists push the frontiers in materials science to solve complex worldwide challenges. The…
IDT Secures contract with Sanofi Australia
Posted: 19 April 2024 IDT Australia Limited (ASX: IDT) (IDT Australia) is pleased to announce that it has entered into a Master Service Agreement with Sanofi, an innovative global healthcare company, to support the preclinical formulation development and…
